Canada markets close in 3 hours 55 minutes
  • S&P/TSX

    18,706.35
    -272.66 (-1.44%)
     
  • S&P 500

    3,664.53
    -79.99 (-2.14%)
     
  • DOW

    29,452.93
    -474.01 (-1.58%)
     
  • CAD/USD

    0.7304
    +0.0027 (+0.38%)
     
  • CRUDE OIL

    92.47
    +4.02 (+4.54%)
     
  • BTC-CAD

    26,796.07
    -810.94 (-2.94%)
     
  • CMC Crypto 200

    446.26
    -8.77 (-1.93%)
     
  • GOLD FUTURES

    1,710.10
    -10.70 (-0.62%)
     
  • RUSSELL 2000

    1,712.77
    -39.75 (-2.27%)
     
  • 10-Yr Bond

    3.8550
    +0.0290 (+0.76%)
     
  • NASDAQ

    10,739.63
    -333.68 (-3.01%)
     
  • VOLATILITY

    31.22
    +0.70 (+2.29%)
     
  • FTSE

    6,991.09
    -6.18 (-0.09%)
     
  • NIKKEI 225

    27,116.11
    -195.19 (-0.71%)
     
  • CAD/EUR

    0.7466
    +0.0040 (+0.54%)
     

Aequus Resumes Trading on TSX Venture Exchange

·3 min read
Aequus Pharmaceuticals
Aequus Pharmaceuticals

VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trading on the TSX Venture exchange tomorrow, July 14, 2022.

Doug Janzen noted that “We will be taking steps to lower the risk of this ever happening again. We are excited about the new Scope products announced last week and plan to have other items to add to our product menu in the coming months.”

Forward-Looking Statements

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the anticipated trading resumption and timing thereof on the TSX Venture Exchange and plans to have other items to add to the Company’s product menu in the coming months. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s final short-form prospectus dated November 5, 2021, and annual information form dated June 30, 2022, copies of which are available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906